fbpx
Size of letters 1x
Site color
Image
Additionally
Line height
Letter spacing
Font
Embedded items (videos, maps, etc.)
 

Farmak released 22 new medicines in 2023

15/ 01/ 2024
  The leader of the Ukrainian pharmaceutical market, Farmak, has released 22 new medicines during 2023. New medicines are intended for the relief of neurological symptoms, for sedation, the treatment of chronic obstructive pulmonary disease, allergic conjunctivitis, fungal infections, glaucoma, sedatives, etc. Among the new products, the company introduced to the market a medicine designed to prevent heart failure. And, what is important, it costs three times less than foreign-made drugs available on the market in Ukraine, while not inferior to them in quality. Farmak continues to invest in the development, research and development of new medicines, despite the full-scale war. In 2023, the company’s investments amounted to about UAH 1.5 billion. Of this, almost 600 million UAH was invested in R&D (note research and development). Farmak’s product portfolio includes more than 400 types of medicines. These are endocrinological, gastroenterological, cardiological, neurological, gynecological, anti-cold and other medications. The company exports its own products to 60 countries, including 15 EU countries, Central and South America, the Middle East, Asia, Africa and Australia. At the end of 2024, Farmak plans to launch pharmaceutical production in Barcelona, Spain.

The leader of the Ukrainian pharmaceutical market, Farmak, has released 22 new medicines during 2023. New medicines are intended for the relief of neurological symptoms, for sedation, the treatment of chronic obstructive pulmonary disease, allergic conjunctivitis, fungal infections, glaucoma, sedatives, etc.

Among the new products, the company introduced to the market a medicine designed to prevent heart failure. And, what is important, it costs three times less than foreign-made drugs available on the market in Ukraine, while not inferior to them in quality.

Farmak continues to invest in the development, research and development of new medicines, despite the full-scale war. In 2023, the company’s investments amounted to about UAH 1.5 billion. Of this, almost 600 million UAH was invested in R&D (note research and development).

Farmak’s product portfolio includes more than 400 types of medicines. These are endocrinological, gastroenterological, cardiological, neurological, gynecological, anti-cold and other medications. The company exports its own products to 60 countries, including 15 EU countries, Central and South America, the Middle East, Asia, Africa and Australia. At the end of 2024, Farmak plans to launch pharmaceutical production in Barcelona, Spain.

This material is provided by a member company or partner organization of the European Business Association as part of an informational collaboration. The Association is not responsible for the accuracy, completeness, or reliability of the information presented. The views, opinions, and recommendations expressed in this material are solely those of the authors and do not reflect the official position of the European Business Association.

If you have found a spelling error, please, notify us by selecting that text and pressing Ctrl+Enter.

Start
in the Telegram bot
Read articles. Share in social networks
Nationwide Minute of Silence
01:00
09:00
Nationwide Minute of Silence
Let us honor the memory of all those who lost their lives in russia’s war against Ukraine
00:43

Spelling error report

The following text will be sent to our editors: